Syntekabio to Showcase AI Drug Discovery Platforms at UKC 2022

Syntekabio will present its AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the UKC 2022 on August 19, showcasing advancements in drug development. Dr. Kilyoung Kim will lead the presentation at the event, which aims to foster networking between American and Korean professionals in science and technology.

Syntekabio, a leading company in AI-driven drug discovery and development, will showcase its state-of-the-art cloud platforms, DeepMatcher® and NEO-ARS™, at the 2022 US-Korea Conference (UKC) on August 19 in Arlington, Virginia. These innovative technologies are set to launch this September and promise to significantly advance drug discovery processes. The conference will foster collaboration between American and Korean professionals in science and technology, providing a platform for networking and sharing insights on cross-border business opportunities. Dr. Kilyoung Kim, CSO and President of Syntekabio USA, will present the company’s latest advancements in AI drug development.

For further information, please visit the event’s webpage.

Founded in 2009, Syntekabio is a South Korean-based company specializing in artificial intelligence and big data applications for drug discovery and development. The company aims to create transformative medicines that adhere to international standards, significantly improving patient care. The upcoming launch of DeepMatcher® and NEO-ARS™ represents a pivotal moment for Syntekabio as it highlights its commitment to innovation within the pharmaceutical industry. Additionally, the UKC serves as a vital meeting point for entrepreneurs and industry leaders to discuss and cultivate cooperation between the United States and Korea, especially in the fields of science and technology.

In summary, Syntekabio’s participation in the UKC 2022 marks a significant advancement in AI-based drug discovery with the introduction of its innovative platforms, DeepMatcher® and NEO-ARS™. The event provides an essential opportunity to promote collaboration between professionals from the United States and Korea and to showcase cutting-edge technologies aimed at enhancing drug discovery processes. Syntekabio continues to play a crucial role in the evolution of pharmaceutical development, demonstrating its dedication to improving lives through innovative medicines.

Original Source: www.globenewswire.com